Graphite Bio, Inc.
NasdaqGM:GRPH Rapporto sulle azioni
Cap. di mercato: US$190.4m
This company is no longer active The company may no longer be operating, as it may be out of business. Find out why through their latest events.
See Latest Events Graphite Bio Dividendi e riacquisti
Dividendo criteri di controllo 0/6 Graphite Bio non ha registrato alcun pagamento di dividendi.
Informazioni chiave
n/a
Rendimento del dividendo
-0.1%
Rendimento del riacquisto
Rendimento totale per gli azionisti -0.1% Rendimento futuro dei dividendi 0% Crescita dei dividendi n/a Prossima data di pagamento dei dividendi n/a Data di stacco del dividendo n/a Dividendo per azione n/a Rapporto di remunerazione n/a
Aggiornamenti recenti su dividendi e riacquisti
Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024 Mar 10
Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024 Mar 09
Mostra tutti gli aggiornamenti Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from NASDAQ Composite Index
New major risk - Share price stability Mar 21
Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024 Mar 10
Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024 Mar 09 LENZ Therapeutics, Inc. entered into a definitive merger agreement to acquire Graphite Bio, Inc. (NasdaqGM:GRPH) for approximately $230 million in a reverse merger transaction. Nov 17
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation Sep 20
Graphite Bio, Inc. Announces Executive Changes Aug 24
Graphite Bio, Inc. Appoints Kimberlee C. Drapkin as Independent Director Aug 05
Graphite Bio, Inc Announces Departure of Alethia Young as Chief Financial Officer Jun 24
Graphite Bio, Inc., Annual General Meeting, Jul 19, 2023 Jun 07
We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely Jun 02
Price target decreased by 23% to US$2.83 Apr 25
Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely? Feb 01
Graphite Bio, Inc. Announces Voluntary Pause of Phase 1/2 Cedar Study of Nulabeglogene Autogedtemcel (Nula-Cel) for Sickle Cell Disease Jan 06
Price target decreased to US$10.86 Jan 06
Graphite Bio, Inc. Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting Dec 13
High number of new and inexperienced directors Nov 16
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation Oct 05
Graphite Bio, Inc. Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease Aug 12
Graphite Bio doses first patient with GPH101 for sickle cell disease Aug 11 Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from Russell 2500 Value Index
Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely? Jun 22
Graphite Bio: Selling For Much Less Than Net Cash May 25
Graphite Bio, Inc. Presents Preclinical Gene Replacement Data for GPH102 for Beta-Thalassemia at the ASGCT 25 Annual Meeting May 18
Graphite Bio, Inc., Annual General Meeting, Jun 21, 2022 May 02
High number of new and inexperienced directors Apr 27 Graphite Bio, Inc. Announces Management Changes
Graphite Bio, Inc. Announces Executive Changes Mar 03
High number of new and inexperienced directors Jan 01
Graphite Bio, Inc. Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition Dec 12
Graphite Bio: An Important Stock To Track In The Gene Editing Space Nov 18
Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans Sep 25
Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr Aug 30
Graphite Bio, Inc. has completed an IPO in the amount of $238 million. Jun 26
Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di GRPH siano rimasti stabili in passato.
Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di GRPH siano aumentati.
Rendimento dei dividendi rispetto al mercato Graphite Bio Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di GRPH rispetto al mercato? Segmento Rendimento dei dividendi Azienda (GRPH) n/a Fondo del 25% del mercato (US) 1.4% Top 25% del mercato (US) 4.4% Media del settore (Biotechs) 2.1% Analista previsionale (GRPH) (fino a 3 anni) 0%
Dividendo notevole: Impossibile valutare il rendimento dei dividendi di GRPH rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Dividendo elevato: Impossibile valutare il rendimento dei dividendi di GRPH rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Distribuzione degli utili agli azionisti
Copertura degli utili: Dati insufficienti per calcolare il payout ratio di GRPH per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché GRPH non ha segnalato alcun pagamento.
Scoprire le società che pagano dividendi forti Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
